Otonomy Announces Patent Grant in United Kingdom
SAN DIEGO, April 7 /PRNewswire/ -- Otonomy, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2459910, titled, "Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders."
This is the first patent granted of a large estate filed by Otonomy to broadly cover its products and technology platform. The company is using this technology for the local delivery of sustained release drug formulations for the treatment of otic disorders including Meniere's disease and sudden sensorineural hearing loss.
"The issuance of this first patent is a significant milestone that confirms our ability to gain full protection for our sustained release products beginning with OTO-104," said Jay Lichter, Ph.D., CEO and co-founder of Otonomy. "In addition, we believe this action validates the novel characteristics of our otic drug delivery approach, and supports our effort to build a leading position in this emerging field."
The newly granted claims cover sustained release formulations of various steroids, including dexamethasone, that are relevant for the treatment of patients with hearing and balance disorders. The claims also cover pharmaceutical properties of these compositions that are necessary for a safe and well-tolerated otic formulation, such as sterility, pH, and osmolarity.
About Otonomy, Inc.
Otonomy is a clinical stage biopharmaceutical company developing novel drug therapies for disorders of the inner and middle ear. The company's core technology is a sustained release formulation developed for optimal delivery of drugs from a single intratympanic (IT) injection. Broad applicability of this delivery and formulation technology has already been established across a number of therapeutic classes, and two products have been advanced into active development. The first, OTO-104, is a sustained release formulation of the steroid dexamethasone. A clinical trial has been initiated in Meniere's disease patients, and future studies are being planned for acute hearing loss. Otonomy's second product, OTO-203, is a sustained release antibiotic being developed for the treatment of otitis media.
Media Contact Heidi Chokeir, Ph.D. Russo Partners O (619) 528-2217 M (858) 380-6584 email@example.com
SOURCE Otonomy, Inc.